These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 34268058)

  • 21. Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.
    Savi D; Lucca F; Tridello G; Meneghelli I; Comello I; Tomezzoli S; Signorini M; Proietti E; Cucchetto G; Volpi S; Cipolli M
    Respir Med; 2023; 219():107406. PubMed ID: 37690570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.
    Bacalhau M; Camargo M; Magalhães-Ghiotto GAV; Drumond S; Castelletti CHM; Lopes-Pacheco M
    Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.
    Burgel PR; Sermet-Gaudelus I; Girodon E; Durieu I; Houdouin V; Audousset C; Macey J; Grenet D; Porzio M; Murris-Espin M; Reix P; Baravalle M; Belleguic C; Mely L; Verhille J; Weiss L; Reynaud-Gaubert M; Mittaine M; Hamidfar R; Ramel S; Cosson L; Douvry B; Danner-Boucher I; Foucaud P; Roy C; Burnet E; Raynal C; Audrezet MP; Da Silva J; Martin C;
    Lancet Respir Med; 2024 Aug; ():. PubMed ID: 39151434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy.
    Stanke F; Pallenberg ST; Tamm S; Hedtfeld S; Eichhorn EM; Minso R; Hansen G; Welte T; Sauer-Heilborn A; Ringshausen FC; Junge S; Tümmler B; Dittrich AM
    Front Pharmacol; 2023; 14():1114584. PubMed ID: 36778025
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis.
    Zhang L; Albon D; Jones M; Bruschwein H
    Ther Adv Respir Dis; 2022; 16():17534666221144211. PubMed ID: 36562554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real world outcomes of CFTR modulator therapy in Australian adults and children.
    Kuek S; McCullagh A; Paul E; Armstrong D
    Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
    Giallongo A; Parisi GF; Papale M; Manti S; Mulé E; Aloisio D; Terlizzi V; Rotolo N; Leonardi S
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
    Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
    Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review.
    Dawood SN; Rabih AM; Niaj A; Raman A; Uprety M; Calero MJ; Villanueva MRB; Joshaghani N; Villa N; Badla O; Goit R; Saddik SE; Mohammed L
    Cureus; 2022 Sep; 14(9):e29359. PubMed ID: 36284811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor.
    Tsai A; Wu SP; Haseltine E; Kumar S; Moskowitz SM; Panorchan P; Shah K
    Pulm Ther; 2020 Dec; 6(2):275-286. PubMed ID: 32734574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
    Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
    Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.
    Heo S; Young DC; Safirstein J; Bourque B; Antell MH; Diloreto S; Rotolo SM
    J Cyst Fibros; 2022 Mar; 21(2):339-343. PubMed ID: 34742667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway.
    Shaughnessy CA; Yadav S; Bratcher PE; Zeitlin PL
    Am J Physiol Lung Cell Mol Physiol; 2022 Mar; 322(3):L305-L314. PubMed ID: 35020527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS/MS Method.
    Pigliasco F; Cafaro A; Stella M; Baiardi G; Barco S; Pedemonte N; D'Orsi C; Cresta F; Casciaro R; Castellani C; Calevo MG; Mattioli F; Cangemi G
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature.
    Tupayachi Ortiz MG; Baumlin N; Yoshida M; Salathe M
    Heliyon; 2024 Mar; 10(5):e26955. PubMed ID: 38463894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France.
    Regard L; Martin C; Burnet E; Da Silva J; Burgel PR
    Cells; 2022 May; 11(11):. PubMed ID: 35681464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
    Tümmler B
    Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study.
    Migliorisi G; Collura M; Ficili F; Pensabene T; Bongiorno D; Collura A; Di Bernardo F; Stefani S
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis.
    Gabillard-Lefort C; Casey M; Glasgow AMA; Boland F; Kerr O; Marron E; Lyons AM; Gunaratnam C; McElvaney NG; Reeves EP
    Am J Respir Crit Care Med; 2022 Apr; 205(7):783-794. PubMed ID: 35021019
    [No Abstract]   [Full Text] [Related]  

  • 40. Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype.
    Comegna M; Terlizzi V; Salvatore D; Colangelo C; Di Lullo AM; Zollo I; Taccetti G; Castaldo G; Amato F
    Antibiotics (Basel); 2021 Jul; 10(7):. PubMed ID: 34356748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.